Back to 13F data
Q1 2026
BIOCRYST PHARMACEUTICALS INC
Original CUSIPs: 09058V103. This page shows current managers, quarterly changes, and primary SEC sources.
Current managers
1
Combined value
$6.1M
Current managers
1
Calculated from each manager’s latest available 13F.
Total shares
638,054
Aggregated at company level with original CUSIP details preserved.
Combined value
$6.1M
Market values are added across managers reporting the same quarter.
Themes
Unclassified
Local mappings are used only for search and classification.
Four-quarter trend
Four-quarter ownership trend
Manager actions by quarter
Current tracked managers holding this company
| Manager | Quarter | Market value | Shares | Portfolio weight | Current-quarter change | Share change | Value change | SEC source |
|---|---|---|---|---|---|---|---|---|
| Bridgewater Associates Ray Dalio / Bridgewater | Q1 2026 | $6,074,274 | 638,054 | 0.03% | Increased +170.85% | +402,482 | +$4,236,812 | XML 05/15/2026 |
Original CUSIP details
| Manager | Issuer | CUSIP | Security class | Market value | Shares | Weight | Source |
|---|---|---|---|---|---|---|---|
| Bridgewater Associates | BIOCRYST PHARMACEUTICALS INC | 09058V103 | COM | $6,074,274 | 638,054 | 0.03% | SEC XML |
Quarterly holdings details
| Quarter | Current managers | Combined value | Total shares | Manager details |
|---|---|---|---|---|
| Q2 2025 | 0 | $0 | 0 | |
| Q3 2025 | 1 | $3,123,308 | 411,503 | Bridgewater Associates New position |
| Q4 2025 | 1 | $1,837,462 | 235,572 | Bridgewater Associates Reduced |
| Q1 2026 | 1 | $6,074,274 | 638,054 | Bridgewater Associates Increased |
Data source
Holdings facts come from SEC 13F information tables. Tickers, company aliases, and themes are used only for search and normalized display, not as a holdings source.